140 related articles for article (PubMed ID: 12200645)
1. Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.
Isaia GC; Lala R; Defilippi C; Matarazzo P; Andreo M; Roggia C; Priolo G; de Sanctis C
Calcif Tissue Int; 2002 Aug; 71(2):121-8. PubMed ID: 12200645
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
Zacharin M; O'Sullivan M
J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
[TBL] [Abstract][Full Text] [Related]
4. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
7. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Lala R; Matarazzo P; Andreo M; Marzari D; Bellone J; Corrias A; de Sanctis C;
J Pediatr Endocrinol Metab; 2006 May; 19 Suppl 2():583-93. PubMed ID: 16789621
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood.
Chan B; Zacharin M
J Pediatr Endocrinol Metab; 2006 Jan; 19(1):75-80. PubMed ID: 16509531
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
11. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Parisi MS; Oliveri B; Mautalen CA
Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
[TBL] [Abstract][Full Text] [Related]
13. Accelerated bone turnover in pregnant women with McCune-Albright syndrome.
Osada H; Sakamoto R; Seki K; Sekiya S
Gynecol Obstet Invest; 2005; 60(2):102-7. PubMed ID: 15860920
[TBL] [Abstract][Full Text] [Related]
14. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
15. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
[TBL] [Abstract][Full Text] [Related]
17. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats.
Brzóska MM; Moniuszko-Jakoniuk J
Bone; 2004 Nov; 35(5):1180-91. PubMed ID: 15542044
[TBL] [Abstract][Full Text] [Related]
18. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia.
Parisi MS; Oliveri MB; Mautalen CA
J Clin Densitom; 2001; 4(2):167-72. PubMed ID: 11477309
[TBL] [Abstract][Full Text] [Related]
20. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]